Rituximab treatment in children with difficult-to-treat nephrotic syndrome
Abstract
Purpose: Rituximab (RTX) has been offered as rescue therapy for patients with difficult-to-treat nephrotic syndrome (frequent relapsing, steroid-dependent and steroid resistant). We aimed to assess the efficacy and long-term outcomes of RTX treatment in children with difficult nephrotic syndrome and shared our experiences
Materials and Methods: Medical records of children with difficult nephrotic syndrome who were treated with RTX were retrospectively evaluated. The relapse-free survival rate at 12 month and monitoring of B-cell depletion were assessed.
Results: In the study included 20 children of which 8 had steroid-dependent (SDNS), 6 had frequent relapsing (FRNS), and 6 had steroid-resistant nephrotic syndrome (SRNS). The median number of relapses at 1 year before and after treatment in FRNS/SDNS patients receiving RTX treatment were compared. The median number of relapses decreased from 2 (1-4) to 0 (0-1) times/year. The mean duration of the follow-up period after RTX treatment was 23 (12-59) months, and 8 patients developed relapse. Repeated doses of RTX were administered to 5 patients who relapsed after RTX treatment. In these patients, CD19+B cells re-emerged during remission, while depletion of memory B-cells remained.
Conclusion: The RTX treatment prolonged the remission time in FRNS/SDNS patients, but it was ineffective in SRNS patients. It was determined that the RTX doses can be repeated to maintain remission in these patients, and the best memory B-cell counts can help in timing the repeat doses.
Keywords
Rituximab , nephrotic syndrome , memory b-cell count , children
Kaynakça
- 1. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362:629-39.
- 2. International Study of Kidney Disease in Children. Early identification of frequent relapsers among children with minimal change nephrotic syndrome. A report of the International Study of Kidney Disease in Children. J Pediatr. 1982;101:514-8.
- 3. Mekahli D, Liutkus A, Ranchin B, Yu A, Bessenay L, Girardin E et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol. 2009;24:1525-32.
- 4. Husen MV, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol. 2011;26:881-92.
- 5. Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21:193-202.
- 6. Maloney DG, Smith B, Rose A. Rituximab: Mechanism of Action and Resistance. Semin Oncol. 2002;29:2-9.
- 7. Sinha A, Bagga A. Rituximab therapy in nephrotic syndrome: implications for patients’ management. Nat. Rev. Nephrol. 2013;9:154-69.
- 8. Schwartz GJ , Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629-37.
- 9. Kallash M, Smoyer WE, Mahan JD. Rituximab use in the management of childhood nephrotic syndrome. Front Pediatr 2019;7:178.
- 10. Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E et al. Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci. 2018;1412:82-9.
